NCT01697020View on ClinicalTrials.gov

Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Mercaptopurine 20mg/ml oral suspension

50mg

DRUG

Mercaptopurine 50mg tablet

50mg

Trial Locations (1)

Unknown

Parexel International, Bloemfontein Early Phase Clinical Unit, Bloemfontein

Sponsors
All Listed Sponsors
lead

Nova Laboratories Limited

INDUSTRY

NCT01697020 - Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions | Biotech Hunter | Biotech Hunter